Beacon Pointe Advisors’s VanEck Biotech ETF BBH Stock Holding History

Beacon Pointe Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,700	Closed	-$511K	–	1198
2021 Q4	$511K	Buy	2,700 +500	+23%	+$96.4K	0.01%	565
2021 Q3	$445K	Hold	2,200	–	–	0.01%	568
2021 Q2	$444K	Hold	2,200	–	–	0.02%	517
2021 Q1	$386K	Hold	2,200	–	–	0.02%	334
2020 Q4	$373K	Hold	2,200	–	–	0.03%	327
2020 Q3	$357K	Buy	2,200 +500	+29%	+$81.3K	0.03%	272
2020 Q2	$277K	Buy	+1,700	New	+$258K	0.03%	316

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

Beacon Pointe Advisors's BBH Position: Q1 2022 in Review

Beacon Pointe Advisors sold out of VanEck Biotech ETF (BBH) in Q1 2022, closing a stake of 2,700 shares — an estimated $511K sold.

Beacon Pointe Advisors first reported a position in BBH in Q2 2020 and held it in 7 quarters. The position peaked at $511K in Q4 2021. 115 funds tracked by Wall St. Rank hold BBH as of Q1 2022.

Beacon Pointe Advisors reported no remaining VanEck Biotech ETF position as of Q1 2022 after selling out during the quarter.
Beacon Pointe Advisors sold 2,700 VanEck Biotech ETF shares in Q1 2022, an estimated $511K.
Beacon Pointe Advisors first reported a position in VanEck Biotech ETF in Q2 2020 and held it in 7 quarters.
Beacon Pointe Advisors's VanEck Biotech ETF position peaked at $511K in Q4 2021.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2022.

Based on Beacon Pointe Advisors's 13F filing for Q1 2022, filed 17 May 2022.